| Symbol | ALZN |
|---|---|
| Name | ALZAMEND NEURO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3480 PEACHTREE ROAD NE,SECOND FLOOR SUITE 103, ATLANTA, Georgia, 30326, United States |
| Telephone | +1 844 722-6303 |
| Fax | — |
| — | |
| Website | https://www.alzamend.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimers. Its mission is to develop and market safe and effective treatments. The companys pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patients immunological system to combat Alzheimers. Additional info from NASDAQ: |
AULT MILTON C III 🟢 acquired 108.4K shares of Alzamend Neuro, Inc. (ALZN) at $1.00 Transaction Date: Apr 14, 2026 | Filing ID: 004742
Read moreAlzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Read moreAlzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreAlzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Read moreAlzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Read moreAlzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06921590 | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an A… | Phase1 | Pharmacokinetics | Active_Not_Recruiting | 2025-05-09 | 2025-12-01 | ClinicalTrials.gov |
| NCT05834296 | Study in Subjects With Mild-to-Moderate Alzheimer's Dementia | Phase1 | Alzheimer Disease | Active_Not_Recruiting | 2023-07-05 | 2028-03-03 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Lithium Carbonate Capsule | DRUG | Phase PHASE1 | Pharmacokinetics | ACTIVE_NOT_RECRUITING | NCT06921590 |
| ALZN002 (autologous DCs pulsed with E22W mutant peptide). | BIOLOGICAL | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05834296 |
| Placebo | DRUG | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05834296 |
| AL001 | DRUG | Phase PHASE1 | Pharmacokinetics | ACTIVE_NOT_RECRUITING | NCT06921590 |